Yüklüyor......
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
The discovery of the Janus kinase (JAK)2 V617F mutation in patients with myeloproliferative neoplasms was a major milestone in understanding the biology of those disorders. Several groups simultaneously reported on the high incidence of this mutation in patients with myeloproliferative neoplasms: al...
Kaydedildi:
| Yayımlandı: | Expert Rev Anticancer Ther |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5176249/ https://ncbi.nlm.nih.gov/pubmed/19445582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.09.14 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|